ArticleCureus2025
Endometrial Cancer in Young Women: Insights From a Tunisian Cohort.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Endometrial cancer (EC) is typically diagnosed after menopause but can also occur in women under 40 years. In this younger subgroup, tumors are often low-grade and confined to the uterus, yielding favorable outcomes. The management of these patients raises the unique challenge of preserving fertility without compromising oncologic safety. Data from North Africa remain scarce. Methods We retrospectively reviewed medical records of women aged ≤40 years diagnosed with EC in the central region of Tunisia between January 2010 and December 2022. Clinical, pathological, imaging, and treatment data were analyzed. Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 26.0 (Released 2019; IBM Corp., Armonk, New York, United States). Survival outcomes were estimated using the Kaplan-Meier method and compared with the log-rank test. Results Twenty-four patients were included, representing 6.3% of all 381 EC cases diagnosed at our institution between 2010 and 2022. The mean age was 34 years (range: 22-40). A history of infertility was reported in 19 of 24 patients (79.2%), preceding the diagnosis of cancer, and obesity was found in 14 (58.3%). Endometrioid adenocarcinoma was predominant in 16/24 (66.7%), followed by non-endometrioid histologies, including endometrial sarcoma (29.2%) and clear cell carcinoma (4.2%). Eight patients (33.3%) received fertility-sparing treatment consisting of oral high-dose progestins and/or a levonorgestrel-releasing intrauterine device. Adjuvant therapy, including radiotherapy, chemotherapy, or combined chemoradiotherapy, was administered to eight patients (33.3%), with no postoperative hormone therapy. Conclusion EC in women under 40 years is uncommon but generally associated with favorable outcomes. This study provides the first dedicated data on young women with EC from central Tunisia. Conventional pathological factors remain the main prognostic determinants in this resource-limited setting. Prospective studies incorporating molecular profiling are needed to refine risk stratification and guide tailored management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.